Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.

OBJECTIVE: To examine the degree to which use of β blockers, statins, and diuretics in patients with impaired glucose tolerance and other cardiovascular risk factors is associated with new onset diabetes. DESIGN: Reanalysis of data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Out...

Full description

Bibliographic Details
Main Authors:	Shen, L, Shah, B, Reyes, E, Thomas, L, Wojdyla, D, Diem, P, Leiter, L, Charbonnel, B, Mareev, V, Horton, E, Haffner, S, Soska, V, Holman, R, Bethel, M, Schaper, F, Sun, J, McMurray, J, Califf, R, Krum, H
Format:	Journal article
Language:	English
Published:	2013

Similar Items

Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
by: Shen, L, et al.
Published: (2012)

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
by: Mcmurray, J, et al.
Published: (2012)

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
by: McMurray, J, et al.
Published: (2012)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
by: Krum, H, et al.
Published: (2010)

Rates of delirium associated with calcium channel blockers compared to diuretics, renin-angiotensin system agents, and beta-blockers: an electronic health records network study
by: Harrison, P, et al.
Published: (2020)

A systematic review and meta-analysis of the effects of diuretics and beta-blockers on glycaemic control in diabetes mellitus
by: Hirst, J, et al.
Published: (2014)

Association of non-alcoholic steatothepatitis with components of the metabolic syndrome in 43,509 patients screened for NAVIGATOR
by: Bethel, A, et al.
Published: (2005)

Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis
by: Hirst, J, et al.
Published: (2015)

Prediabetes and the risk of diabetes.
by: McMurray, J, et al.
Published: (2012)

Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
by: McMurray, J, et al.
Published: (2005)

Determining the most appropriate components for a composite clinical trial outcome.
by: Bethel, M, et al.
Published: (2008)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
by: Califf, R, et al.
Published: (2008)

Diuretic properties of Orthosiphon stamineus Benth.
by: Adam, Yunus, et al.
Published: (2009)

Overview of randomised trials of diuretics in pregnancy.
by: Collins, R, et al.
Published: (1985)

Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design.
by: Kotecha, D, et al.
Published: (2013)

Restructuring and reanalysis
by: Manzini, Maria Rita
Published: (2009)

Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population.
by: Bethel, M, et al.
Published: (2009)

Indapamide: a diuretic of choice for the treatment of hypertension?
by: Clarke, R
Published: (1991)

Diuretic induced gout : a multifactorial condition /
by: 428718 Scott, J. T., et al.

Relations between Baseline Physical Activity by Pedometer Counts and Future Cardiovascular Events in the NAVIGATOR Study
by: Kraus, W, et al.
Published: (2012)

Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR
by: McMurray, J, et al.
Published: (2004)

Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database.
by: de Vries, F, et al.
Published: (2006)

Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database
by: de Vries, F, et al.
Published: (2006)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
by: Currie, G, et al.
Published: (2017)

A reanalysis of two studies that reported contrasting results on the association between statin use and risk of fracture in the same data source
by: de Vries, F, et al.
Published: (2005)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
by: Preiss, D, et al.
Published: (2012)

Rapid development of gouty tophi after diuretic therapy.
by: Wordsworth, B, et al.
Published: (1985)

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR
by: Huffman, K, et al.
Published: (2014)

Metabolomics of beta-blockers
by: Tan, Ian Yong Ming.
Published: (2010)

Increased incidence of diuretic use in critically ill obese patients
by: de Louw, Emma J., et al.
Published: (2016)

Hyperparathyroidism, hypertension and loop diuretic medication in renal transplant recipients.
by: Bittar, A, et al.
Published: (1989)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
by: Yates, T, et al.
Published: (2014)

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.
by: Huffman, K, et al.
Published: (2014)

Association of Baseline Physical Activity by Pedometer Counts and Nutritional Behavior on Metabolic Syndrome in the NAVIGATOR Study
by: Huffman, K, et al.
Published: (2013)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
by: Yates, T, et al.
Published: (2014)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
by: Mcmurray, J, et al.
Published: (2011)

Network device ad-blocker
by: Mohamad, Juhaina, et al.
Published: (2020)

Beta-blockers in cardiac failure.
by: Neubauer, G, et al.
Published: (1994)

beta blockers in hypertension Reply
by: Rothwell, P
Published: (2010)

Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
by: Bethel, M, et al.
Published: (2009)